Earnings Call · Q1 FY2026·2026-05-06

Q1 26EPS -10.00%·Rev n/aQ4 25EPS +23.43%·Rev n/aQ3 25EPS 0.00%·Rev n/aQ2 25EPS -14.29%·Rev n/a⚠ consensus missing

Taysha Gene Therapies, Inc. TSHA

Hayleigh Collins — Investor Relations or Corporate Communications

Sean Nolan — Chief Executive Officer

Sukumar Nagendran — President and Head of R&D

Kamran Alam — CHIEF FINANCIAL OFFICER

+0.6%1d on move date−0.8% vs SPY3d−1.9%5d−1.3%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TSHA calls or request research access.

More TSHA calls Browse calls Request research access